Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor for prevention of major cardiovascular events in high-risk patients with type 2 diabetes mellitus
NL-OMON47716Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity, type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis comparing ticagrelor with placebo (2 arms). Started Feb 2014; status: active, not recruiting.
02
Drugs
ticagrelor
03
Conditions
cardiac morbiditytype 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON47716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47716.